Brief: Algernon To Adding Lung Scarring As Additional Endpoint For Phase 2B/3 Covid-19 Study Protocol
10/02/2021 12:02
Feb 10 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS CONSIDERS ADDING LUNG SCARRING AS
AN
ADDITIONAL ENDPOINT FOR ITS PHASE 2B/3 COVID-19 STUDY PROTOCOL
Source text for Eikon: ID:nGNX91YzcZ
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement